Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 83


Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia, results from two clinical trials.

Schlenk R, Krauter J, Raffoux E, Kreuzer KA, Schaich M, Noens L, Pabst T, Vusirikala M, Bouscary D, Spencer A, Candoni A, Sierra Gil J, Berkowitz N, Weber HJ, Ottmann O.

Haematologica. 2017 Oct 19. pii: haematol.2017.172411. doi: 10.3324/haematol.2017.172411. [Epub ahead of print] No abstract available.


International, prospective haemovigilance study on methylene blue-treated plasma.

Noens L, Vilariño MD, Megalou A, Qureshi H.

Vox Sang. 2017 May;112(4):352-359. doi: 10.1111/vox.12510. Epub 2017 Mar 26.


Hand grip strength as a screening tool for frailty in older patients with haematological malignancies.

Velghe A, De Buyser S, Noens L, Demuynck R, Petrovic M.

Acta Clin Belg. 2016 Aug;71(4):227-30. doi: 10.1080/17843286.2016.1162381. Epub 2016 Apr 27.


Combined evaluation of conventional MRI, dynamic contrast-enhanced MRI and diffusion weighted imaging for response evaluation of patients with multiple myeloma.

Dutoit JC, Claus E, Offner F, Noens L, Delanghe J, Verstraete KL.

Eur J Radiol. 2016 Feb;85(2):373-82. doi: 10.1016/j.ejrad.2015.11.040. Epub 2015 Dec 2.


Correction: Validation of High Resolution Melting Analysis (HRM) of the Amplified ITS2 Region for the Detection and Identification of Yeasts from Clinical Samples: Comparison with Culture and MALDI-TOF Based Identification.

Duyvejonck H, Cools P, Decruyenaere J, Roelens K, Noens L, Vermeulen S, Claeys G, Decat E, Van Mechelen E, Vaneechoutte M.

PLoS One. 2015 Sep 25;10(9):e0139501. doi: 10.1371/journal.pone.0139501. eCollection 2015. No abstract available.


Validation of High Resolution Melting Analysis (HRM) of the Amplified ITS2 Region for the Detection and Identification of Yeasts from Clinical Samples: Comparison with Culture and MALDI-TOF Based Identification.

Duyvejonck H, Cools P, Decruyenaere J, Roelens K, Noens L, Vermeulen S, Claeys G, Decat E, Van Mechelen E, Vaneechoutte M.

PLoS One. 2015 Aug 21;10(8):e0132149. doi: 10.1371/journal.pone.0132149. eCollection 2015. Erratum in: PLoS One. 2015;10(9):e0139501.


Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey.

Beguin Y, Selleslag D, Meers S, Graux C, Bries G, Deeren D, Vrelust I, Ravoet C, Theunissen K, Voelter V, Potier H, Trullemans F, Noens L, Mineur P.

Acta Clin Belg. 2015 Feb;70(1):34-43. doi: 10.1179/2295333714Y.0000000102. Epub 2014 Dec 2.


Myelofibrosis patients in Belgium: disease characteristics.

Devos T, Zachée P, Bron D, Noens L, Droogenbroeck JV, Mineur P, Beguin Y, Berneman Z, Benghiat FS, Kentos A, Chatelain C, Demuynck H, Lemmens J, Eygen KV, Theunissen K, Trullemans F, Pierre P, Pluymers W, Knoops L.

Acta Clin Belg. 2015 Apr;70(2):105-11. doi: 10.1179/2295333714Y.0000000097. Epub 2014 Nov 6.


Plerixafor prescription modalities in autologous haematopoietic stem cell mobilization in Belgium.

Selleslag D, Lambert C, Zachee P, Huyngh P, Van de Velde A, Noens L, Baily L, André M, Willems E, Dierickx D.

Acta Clin Belg. 2015 Feb;70(1):16-22. doi: 10.1179/2295333714Y.0000000077. Epub 2014 Sep 18.


Validation of the G8 screening tool in older patients with aggressive haematological malignancies.

Velghe A, Petrovic M, De Buyser S, Demuynck R, Noens L.

Eur J Oncol Nurs. 2014 Dec;18(6):645-8. doi: 10.1016/j.ejon.2014.05.006. Epub 2014 Jun 20.


Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes.

Delforge M, Selleslag D, Beguin Y, Triffet A, Mineur P, Theunissen K, Graux C, Trullemans F, Boulet D, Van Eygen K, Noens L, Van Steenweghen S, Lemmens J, Pierre P, D'hondt R, Ferrant A, Deeren D, Van De Velde A, Wynendaele W, André M, De Bock R, Efira A, Breems D, Deweweire A, Geldhof K, Pluymers W, Harrington A, MacDonald K, Abraham I, Ravoet C.

Leuk Res. 2014 May;38(5):557-63. doi: 10.1016/j.leukres.2014.02.003. Epub 2014 Feb 14.


Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges.

Noens L, Hensen M, Kucmin-Bemelmans I, Lofgren C, Gilloteau I, Vrijens B.

Haematologica. 2014 Mar;99(3):437-47. doi: 10.3324/haematol.2012.082511. Review.


Management of myelodysplastic syndromes in adults: guidelines from the Belgian Haematological Society.

Meers S, Breems D, Bries G, Delforge M, Graux C, Ravoet C, Selleslag D, Noens L; Belgian Haematological Society.

Acta Clin Belg. 2013 Jul-Aug;68(4):253-62.


Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma.

Thomas SK, Suvorov A, Noens L, Rukavitsin O, Fay J, Wu KL, Zimmerman TM, van de Velde H, Bandekar R, Puchalski TA, Qi M, Uhlar C, Samoylova OS.

Cancer Chemother Pharmacol. 2014 Jan;73(1):35-42. doi: 10.1007/s00280-013-2314-7. Epub 2013 Oct 23.


International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24.

Efficace F, Baccarani M, Breccia M, Saussele S, Abel G, Caocci G, Guilhot F, Cocks K, Naeem A, Sprangers M, Oerlemans S, Chie W, Castagnetti F, Bombaci F, Sharf G, Cardoni A, Noens L, Pallua S, Salvucci M, Nicolatou-Galitis O, Rosti G, Mandelli F.

Qual Life Res. 2014 Apr;23(3):825-36. doi: 10.1007/s11136-013-0523-5. Epub 2013 Sep 13.


Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.

Kuendgen A, Lauseker M, List AF, Fenaux P, Giagounidis AA, Brandenburg NA, Backstrom J, Glasmacher A, Hasford J, Germing U; International Working Group on MDS with del(5q).

Leukemia. 2013 Apr;27(5):1072-9. doi: 10.1038/leu.2012.369. Epub 2012 Dec 21.


Long-term outcomes and quality of life in critically ill patients with hematological or solid malignancies: a single center study.

Oeyen SG, Benoit DD, Annemans L, Depuydt PO, Van Belle SJ, Troisi RI, Noens LA, Pattyn P, Decruyenaere JM.

Intensive Care Med. 2013 May;39(5):889-98. doi: 10.1007/s00134-012-2791-x. Epub 2012 Dec 18.


Early recognition of malignant lactic acidosis in clinical practice: report on 6 patients with haematological malignancies.

De Raes EA, Benoit DD, Depuydt PO, Offner F, Nollet J, Vantilborgh AK, Steel E, Noens LA, Decruyenaere JM.

Acta Clin Belg. 2012 Sep-Oct;67(5):347-51.


Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.

Lugtenburg P, Silvestre AS, Rossi FG, Noens L, Krall W, Bendall K, Szabo Z, Jaeger U.

Clin Lymphoma Myeloma Leuk. 2012 Oct;12(5):297-305. doi: 10.1016/j.clml.2012.06.004.


High-risk clonal evolution in chronic B-lymphocytic leukemia: single-center interphase fluorescence in situ hybridization study and review of the literature.

Janssens A, Van Roy N, Poppe B, Noens L, Philippé J, Speleman F, Offner F.

Eur J Haematol. 2012 Jul;89(1):72-80. doi: 10.1111/j.1600-0609.2012.01790.x. Epub 2012 May 7.


Supplemental Content

Loading ...
Support Center